Poolbeg Pharma PLC (AIM:POLB) Attendance at European Melioidosis Congress

Poolbeg to engage with key international stakeholders at congress as it develops

an intramuscular Melioidosis vaccine candidate

11 May 2022 – Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’), a clinical stage infectious disease pharmaceutical company with a unique capital light clinical model, is participating in the European Melioidosis Congress (EMC) 2022, due to take place 16 May 2022 – 18 May 2022 in Graz, Austria, as it develops a Melioidosis vaccine candidate.

Poolbeg currently holds an option from University College Dublin to licence a late pre-clinical stage Melioidosis vaccine (POLB 003). There is currently no available vaccine on the market for Melioidosis, an infectious disease which is widespread in tropical and subtropical regions such as Northern Australia and Southeast Asia, with rising incidence around the world due to climate change. Caused by the bacteria Burkholderia pseudomallei, Melioidosis is intrinsically resistant to antibiotics and has global mortality rates up to 70%, depending on geography and bacterial load.

Learn more about POLB 003 here.

Jeremy Skillington, PhD, CEO of Poolbeg Pharma said: “Melioidosis presents a growing threat to health as a result of climate change, and is currently an infectious disease with no approved vaccine and a high mortality rate. At Poolbeg we are focused on targeting the significant global medical need to treat and prevent infectious diseases such as Melioidosis and we look forward to engaging with key scientific opinion leaders involved in the global effort to tackle and eliminate Melioidosis at the upcoming European Melioidosis Congress”.

– Ends –


Poolbeg Pharma Plc

Jeremy Skillington, CEO

Ian O’Connell, CFO

+44 (0) 207 183 1499

Linking Shareholders and Executives :Share Talk

If anyone reads this article found it useful, helpful? Then please subscribe www.share-talk.com or follow SHARE TALK on our Twitter page for future updates. Terms of Website Use All information is provided on an as-is basis. Where we allow Bloggers to publish articles on our platform please note these are not our opinions or views and we have no affiliation with the companies mentioned
Share Talk
Malcare WordPress Security